%0 Journal Article %1 Vincenzi.2007 %A Vincenzi, B. %A Santini, D. %A Russo, A. %A Gavasci, M. %A Battistoni, F. %A Dicuonzo, G. %A Rocci, L. %A Rosaria, V. M. %A Gebbia, N. %A Tonini, G. %D 2007 %J Pharmacogenomics. %K & A Adult Aged Antibodies Antineoplastic Biological Camptothecin Chemotherapy Colorectal Combined Disease Endothelial Factor Female Growth Humans Male Markers Medical Middle Monoclonal Neoplasms Oncology Outcome Progression Prospective Protocols Rate Studies Survival Treatment Tumor Vascular administration analogs antagonists blood derivatives dosage drug inhibitors methods mortality response therapeutic therapy trends use %N 4 %P 319-327 %T Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan %U PM:17391070 %V 8 %X OBJECTIVE: We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS: A total of 45 heavily pretreated metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF during the treatment with cetuximab plus weekly irinotecan. VEGF circulating levels were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. RESULTS: Basal VEGF median levels were significantly decreased just 1 day after the first anticancer infusion (p = 0.016) and reached the highest statistical significance 92 days after the first infusion (p < 0.0001). A total of 22 patients showed a reduction in median VEGF circulating levels of at least 50% 92 days after the first infusion

@article{Vincenzi.2007, abstract = {OBJECTIVE: We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS: A total of 45 heavily pretreated metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF during the treatment with cetuximab plus weekly irinotecan. VEGF circulating levels were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. RESULTS: Basal VEGF median levels were significantly decreased just 1 day after the first anticancer infusion (p = 0.016) and reached the highest statistical significance 92 days after the first infusion (p < 0.0001). A total of 22 patients showed a reduction in median VEGF circulating levels of at least 50% 92 days after the first infusion}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Vincenzi, B. and Santini, D. and Russo, A. and Gavasci, M. and Battistoni, F. and Dicuonzo, G. and Rocci, L. and Rosaria, V. M. and Gebbia, N. and Tonini, G.}, biburl = {https://www.bibsonomy.org/bibtex/223511f1ba021049533daca96017b211a/kanefendt}, interhash = {909e5865f992f6f8b7fee4236788c5f8}, intrahash = {23511f1ba021049533daca96017b211a}, journal = {Pharmacogenomics.}, keywords = {& A Adult Aged Antibodies Antineoplastic Biological Camptothecin Chemotherapy Colorectal Combined Disease Endothelial Factor Female Growth Humans Male Markers Medical Middle Monoclonal Neoplasms Oncology Outcome Progression Prospective Protocols Rate Studies Survival Treatment Tumor Vascular administration analogs antagonists blood derivatives dosage drug inhibitors methods mortality response therapeutic therapy trends use}, number = 4, pages = {319-327}, timestamp = {2010-02-05T11:28:54.000+0100}, title = {Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan}, url = {PM:17391070}, volume = 8, year = 2007 }